Sp910
THE STATE OF NUTRITION EDUCATION IN GI FELLOWSHIP TODAY: WHERE WE’VE COME FROM AND WHERE WE NEED TO GO
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This session, designed for the fellows, clinician educator and program director focuses on designing and delivering curricula for GI fellows on the topics of nutrition, including the obesity epidemic. After a review of the current state and vision or the future, three clinician educators and nutrition experts will highlight resources and approaches to address this vital topics that most training programs struggle to cover. Unique to this session will be the collaboration with a dietician to discuss an approach for interprofessional training in GI using, a core component of ACGME program requirements.
This session, designed for the fellows, clinician educator and program director focuses on designing and delivering curricula for GI fellows on the topics of nutrition, including the obesity epidemic. After a review of the current state and vision or the future, three clinician educators and nutrition experts will highlight resources and approaches to address this vital topics that most training programs struggle to cover. Unique to this session will be the collaboration with a dietician to discuss an approach for interprofessional training in GI using, a core component of ACGME program requirements.
Presenter
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
